Survival analysis for the 318 patients who did not have underlying disease
| No of patients | Mortality (%) | Hazard ratio | ||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis* | |||
| Data shown are hazard ratios with 95% confidence intervals (CI). | ||||
| *Multivariate survival analysis was performed for the 195 patients with complete data. | ||||
| Empirical antibiotic use | ||||
| Fluoroquinolone | 37 | 5 (13.5%) | 6.88 (1.84 to 25.72) | 4.22 (1.01 to 11.82) |
| Others | 116 | 14 (12.1%) | 5.19 (1.71 to 15.79) | 1.36 (0.33 to 5.56) |
| No | 165 | 4 (2.4%) | ||
| Age | ||||
| >65 years | 131 | 19 (14.5%) | 7.08 (2.41 to 20.81) | 6.43 (1.37 to 30.29) |
| ⩽65 years | 187 | 4 (2.1%) | ||
| Involvement of TB | ||||
| Extrapulmonary | 81 | 8 (9.9%) | 1.38 (0.58 to 3.26) | |
| Pulmonary | 237 | 15 (6.3%) | ||
| Respiratory symptoms | ||||
| Yes | 224 | 10 (4.5%) | 0.34 (0.15 to 0.77) | 0.66 (0.20 to 2.16) |
| No | 94 | 13 (13.8%) | ||
| Constitutional symptoms | ||||
| Yes | 105 | 12 (11.4%) | 2.25 (0.99 to 5.10) | |
| No | 213 | 11 (5.2%) | ||
| Duration of symptoms | ||||
| >14 days | 217 | 10 (4.6%) | 0.31 (0.13 to 0.70) | 0.74 (0.26 to 2.10) |
| ⩽14 days | 101 | 13 (12.9%) | ||
| Lower lung field TB | ||||
| Yes | 61 | 4 (6.6%) | 0.89 (0.30 to 2.62) | |
| No | 257 | 19 (7.4%) | ||
| Cavity on chest radiograph | ||||
| Yes | 42 | 3 (7.1%) | 1.03 (0.31 to 3.47) | |
| No | 276 | 20 (7.2%) | ||
| Albumin (g/dl) | ||||
| <35 | 76 | 15 (19.7%) | 15.07 (3.44 to 66.05) | 8.85 (1.96 to 39.94) |
| ⩾35 | 119 | 2 (1.7%) | ||
| Sputum acid-fast smear | ||||
| Positive | 61 | 2 (3.3%) | 0.38 (0.09 to 1.64) | |
| Negative | 257 | 21 (8.2%) | ||
| Anti-TB treatment | ||||
| ⩽14 days after initial visit | 162 | 7 (4.3%) | 0.37 (0.15 to 0.91) | 0.70 (0.51 to 0.97) |
| >14 days after initial visit | 156 | 16 (10.3%) | ||